If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

March 19, 2018 | A version of this story appeared in Volume 96, Issue 12

Huntsman Corp. will pay $350 million to acquire Demilec, a maker of spray polyurethane foam insulation systems. Huntsman says the purchase forward-integrates its methylene diphenyl diisocyanate business.

Agrisoma Biosciences has raised $9.3 million from investors to expand output of the oil seed crop carinata, which is used to produce biojet fuel. Fuel made from the plant, a mustard relative, was used to power a Qantas Airlines flight from Melbourne to Los Angeles in January.

Ascensus Specialties is the new name for Vertellus Performance Chemicals, a producer of sodium borohydride. Ascensus separated from Vertellus Specialties during the latter’s 2016 bankruptcy.

TNO, a Dutch technology institute, and partners are investing $12 million to develop commercial processes for making aromatic chemicals from sugar. Bioaromatics could replace 40% of all chemicals, TNO says.

DuPont has formed a probiotic R&D agreement with the Center of Food & Fermentation Technologies in Tallinn, Estonia. DuPont formed a similar pact with three Irish institutions late last year.

Bruker and the Danish instrument maker Evosep are joining to develop and market a clinical proteomics analysis system. Together, the Evosep One chromatograph and Bruker’s timsTOF Pro mass spectrometer can quantify over 1,000 proteins in five minutes, the partners say.

Escalier Biosciences raised $19 million in series B funding to further develop small molecules that target a nuclear hormone receptor called RORγt to treat psoriasis and other autoimmune diseases. Clinical trials of a topical compound are expected to begin in mid-2018.

Boehringer Ingelheim has formed a third collaboration with Vanderbilt University. The two will build on discoveries from the lab of chemist Stephen W. Fesik to find drugs that inhibit the myeloid cell leukemia 1 protein.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.